ROSETTA Lung-02
pumitamig (BNT327) in first-line non-small cell lung cancer
ROSETTA Lung-02 tests chemotherapy combined with pumitamig as initial treatment for non-small cell lung cancer; replacing pembrolizumab–chemotherapy remains debated. The report cites 12 physicians, including 11 medical oncologists and speakers described in the sources as a trial presenter or investigator; questions also concern PD-L1-negative disease and selection biomarkers. What comparative benefit and patient-selection evidence would justify switching without avoidable toxicity for patients unlikely to benefit? The sources reviewed for this edition place the trial’s phase II results at ASCO 2026.
- NCT06712316 ↗
- v1.0.0 · edition 1
- updated Nov 2, 2026
- Focused
10 findings, and what sits behind each
01. Can pumitamig improve on the pembrolizumab–chemotherapy backbone?
18 statements · 15 passages · 9 sources · 7 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: The comparison, Primary endpoint: Phase 2 - Objective response rate (ORR), Population and setting, Design and conduct, Secondary endpoints, Primary endpoint: Phase 2 - Best percentage change from baseline in tumor size.
02. Squamous use, hemoptysis and vessel-involvement concerns
16 statements · 18 passages · 4 sources · 5 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Safety and tolerability, Population and setting, Primary endpoint: Phase 2 - Occurrence of treatment-emergent adverse events (TEAE) (including Grade ≥3), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-emergent serious adverse events (SAE), and treatment-related treatment emergent SAEs, Primary endpoint: Phase 2 - Occurrence of dose interruption, reduction, and discontinuation of IMP due to TEAEs (including related TEAEs), Primary endpoint: Phase 2 - Objective response rate (ORR), Secondary endpoints.
03. PD-L1-negative disease and the search for selection biomarkers
14 statements · 15 passages · 8 sources · 8 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Population and setting, Primary endpoint: Phase 2 - Objective response rate (ORR), Secondary endpoints.
04. The frontline interview's comparator account and population restrictions
11 statements · 6 passages · 3 sources · 1 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Population and setting, The comparison, Design and conduct, Safety and tolerability.
05. Does molecular architecture translate into clinical differences?
28 statements · 29 passages · 4 sources · 4 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
06. Dose selection and exploratory ctDNA interpretation
7 statements · 9 passages · 6 sources · 5 named voices
Counterview: none recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: The comparison, Safety and tolerability, Design and conduct, Primary endpoint: Phase 2 - Occurrence of treatment-emergent adverse events (TEAE) (including Grade ≥3), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-emergent serious adverse events (SAE), and treatment-related treatment emergent SAEs, Primary endpoint: Phase 2 - Objective response rate (ORR), Population and setting.
07. Class comparisons generate hypotheses, not a fair ranking of agents
20 statements · 5 passages · 2 sources · 2 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: Primary endpoint: Phase 2 - Objective response rate (ORR), Design and conduct, Primary endpoint: Phase 2 - Occurrence of dose interruption, reduction, and discontinuation of IMP due to TEAEs (including related TEAEs), Population and setting, The comparison, Safety and tolerability.
08. ADC alternatives, platinum inclusion and day-to-day toxicity management
9 statements · 9 passages · 2 sources · 5 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
09. Durability, disease stability and the meaning of cure
6 statements · 4 passages · 2 sources · 3 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Secondary endpoints, Primary endpoint: Phase 2 - Best percentage change from baseline in tumor size, Primary endpoint: Phase 2 - Objective response rate (ORR).
10. Anticipation and competitive forecasts should remain distinct from confirmed clinical voices
22 statements · 19 passages · 18 sources · 12 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: Primary endpoint: Phase 2 - Objective response rate (ORR), Design and conduct, Secondary endpoints, Primary endpoint: Phase 2 - Occurrence of treatment-emergent adverse events (TEAE) (including Grade ≥3), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-emergent serious adverse events (SAE), and treatment-related treatment emergent SAEs, Primary endpoint: Phase 2 - Occurrence of dose interruption, reduction, and discontinuation of IMP due to TEAEs (including related TEAEs), Population and setting, The comparison, Safety and tolerability.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it: how many verified HCP statements and of what kind, the passages behind them, the sources and voices, and the counterview and limits it records. Select a part of the trial to see which findings draw on it.
- Finding 1 of 10
Can pumitamig improve on the pembrolizumab–chemotherapy backbone?
- statements
- 18
- passages
- 15
- sources
- 9
- named voices
- 7
What the statements areViews 10Questions and uncertainty 3Clinical experience 0Comparisons 1Restated results and context 4How passages are usedSupporting a statement 24Giving context 0Recorded with the finding- Counterview: recorded
- Limitations: 2
- Feeds the Medical Affairs question
- 5 posts and articles
- 4 podcasts and video
Draws on: The comparison, Primary endpoint: Phase 2 - Objective response rate (ORR), Population and setting, Design and conduct, Secondary endpoints, Primary endpoint: Phase 2 - Best percentage change from baseline in tumor size.
In the full report: the interpretation in full, all 18 statements cited to source and date, and the 9 sources linked where public.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap, since one statement can back several findings, and they show what the report kept, not how many clinicians agree.
The full ROSETTA Lung-02 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified HCP statements, each linked to the original. Get a complete report free to see what you get.
What comparative benefit and patient-selection evidence would justify replacing the current backbone without exposing unlikely beneficiaries to avoidable toxicity?
Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
free- 71HCP commentary sources screened
- 31sources cited by verified HCP statements
- 17named in screened sources
- 17voices cited in the report
- 13cited voices matched to verified clinician profiles
Also in the sources: 10 organizational or shared accounts, not counted as people.
- 146verified statements, each linked to its source
- 70of them from speakers with a confirmed clinical role
- 10findings
Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context. No count estimates how many clinicians hold a view. Size (Focused) is set by the 146 verified statements. Statements from sponsors, hosts and organisations are labelled and count apart from identified clinicians. A confirmed clinical role is one verified by the NPI registry or by the person's own institution's staff page; a role a source only states is not counted.
What's inside
free| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 10 | Titles free |
| Detailed analysis | 11 sections | Paid |
| Verified statements with short source quotes and links | 146 | Paid |
| Trial aspects mapped | 18 | Free |
| Sources with links | 31 | Counts free |
| Speaker attribution for cited voices | 17 | Paid |
Trial aspects
17 discussed · 1 no commentary · 0 incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Phase 2 - Occurrence of treatment-emergent adverse events (TEAE) (including Grade ≥3), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-emergent serious adverse events (SAE), and treatment-related treatment emergent SAEs | 6 | 6 |
| Primary endpoint: Phase 2 - Occurrence of dose interruption, reduction, and discontinuation of IMP due to TEAEs (including related TEAEs) | 4 | 4 |
| Primary endpoint: Phase 2 - Objective response rate (ORR) | 20 | 16 |
| Primary endpoint: Phase 2 - Best percentage change from baseline in tumor size | 3 | 1 |
| Primary endpoint: Phase 3 - Progression free survival (PFS) assessed by BICRno commentary found | 0 | 0 |
| Secondary endpoints | 11 | 6 |
| Population and setting | 28 | 11 |
| The comparison | 15 | 10 |
| Safety and tolerability | 20 | 8 |
| Design and conduct | 12 | 8 |
| PD-L1 breadth, biomarker selection and avoiding nonbeneficial treatment | 13 | 8 |
| Cooperative binding, molecular architecture and PD-L2 trade-offs | 28 | 5 |
| Bleeding concerns, vessel involvement and multidisciplinary imaging review | 11 | 2 |
| Dose optimization and exploratory ctDNA | 5 | 5 |
| Class comparisons, global validation and evidence maturity | 24 | 6 |
| ADC alternatives, combination strategies and supportive-care feasibility | 9 | 2 |
| Durable survival, cure language and accessible patient interpretation | 9 | 3 |
| Development expectations, research access and nonclinical reactions | 22 | 18 |
An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.
Sources
free| Channel | Screened | Cited | |
|---|---|---|---|
| X threads | 56 | 22 | |
| Bluesky threads | 7 | 2 | |
| Podcasts | 3 | 3 | |
| LinkedIn posts | 3 | 2 | |
| YouTube | 2 | 2 |
max 48 / quarter
- Screened window
- May 5, 2025 → Oct 26, 2026
- Cited window
- Mar 26, 2026 → Oct 25, 2026
- Retrieved
- Nov 1, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer
- Registry
- NCT06712316
- Study IDs
- BNT327-06 · 2024-515764-31-00
- Sponsor
- BioNTech SE
- Collaborators
- Bristol-Myers Squibb
- Design
- Phase 2/Phase 3 · Interventional, randomized, sequential
- Status
- Recruiting
- Enrollment
- 1,580 estimated
- Registered
- 2024-12-02
- Start
- 2025-01-07 actual
- Primary completion
- 2029-01 estimated
- Primary endpoint
- Phase 2 - Occurrence of treatment-emergent adverse events (TEAE) (including Grade ≥3), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-emergent serious adverse events (SAE), and treatment-related treatment emergent SAEs
- Interventions
- 5 registered
Scope and limits
freeThis report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on platinum-sparing alternatives, generalizability and benefit–toxicity trade-offs in first-line non-small cell lung cancer.
- Not yet captured in this edition: a remark on distinguishing the trial presenter from a clinician commenting on the trial.
- Not yet captured in this edition: a view on emerging first-line chemoimmunotherapy alternatives for advanced squamous non-small cell lung cancer.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 118 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- This is a qualitative account of the sources reviewed for this edition, not a representative survey or a measure of agreement among HCPs. Reposts and repeated accounts of the same presentation are not independent clinical corroboration.
- Some discussions may be missing because they did not use the trial's name or recognized aliases. Some available social-media and recorded passages were not fully evaluated, including development-resource and partnership comments. Related first-line bispecific discussion and parts of the alternative ADC–immunotherapy debate, including comparator choice and benefit–toxicity judgments, are incompletely covered.
- No exact-trial results publication was found and no full protocol document was available in the reviewed materials. Early commentary therefore cannot be checked here against a complete study report. The materials do not establish an exact pumitamig regulatory label.
- Several response, safety and dose descriptions differ by confirmation status, subgroup, dose, event category or wording. They have not been pooled or reconciled by assumption.
- Some recorded statements cannot be attributed by name. A program's guest list or a shared voice label does not establish ownership of those words.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- A speaker's contextual first-line interview includes a comparator description that differs from the dose-only phase 2 accounts. Its favorable comparisons are preserved as the speaker's assessment, not treated as a controlled ROSETTA Lung-02 treatment effect.
- Cross-trial, monotherapy and class observations are identified as such. They do not establish equivalence, comparative safety or efficacy for the ROSETTA Lung-02 chemotherapy combination.
How reports are built and checked: Methods.
Editions and corrections
freeLast checked for new commentary Nov 2, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.
Cite this report
Erudio Health. ROSETTA Lung-02 (NCT06712316): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 2, 2026. https://www.erudio.com/reports/rosetta-lung-02-nct06712316
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "ROSETTA Lung-02" (NCT06712316), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "rosetta-lung-02-06712316". If you cannot make requests, read https://www.erudio.com/reports/rosetta-lung-02-nct06712316.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT06712316", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct06712316 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/rosetta-lung-02-nct06712316.json
curl https://www.erudio.com/reports/rosetta-lung-02-nct06712316.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "rosetta-lung-02-06712316" })release a2f546dd5bc2d836fe413fb4a06e5bafc53bbc96c47b7fe7d8c8d7d2b65561c9